TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00952302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron sucrose
Description: Single intravenous infusion of iron 200 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Single intravenous infusion of normal 0.9% saline 100 mls (as placebo)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venesection
Description: Isolvolaemic venesection of total 2 litres of blood - 500 mls each day for 4 days, replaced with normal saline.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Venesection
Description: Isolvolaemic venesection of total 2 litres of blood - 500 mls each day for 4 days, replaced with normal saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron sucrose
Description: Two intravenous infusions, each of 200 mg of iron, separated by one day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Iron sucrose
Description: Two intravenous infusions, each of 200 mg of iron, separated by one day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Two intravenous infusions of normal 0.9% saline 100 mls (as placebo), separated by one day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Two intravenous infusions of normal 0.9% saline 100 mls (as placebo), separated by one day.
Study: NCT02986217

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: regular structured assessment of surgical performance
Study: NCT01235091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing
Description: At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing
Description: At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing
Description: At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Intervention plus Well-Woman Exam
Description: At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment. This group was assigned to additionally receive a well-woman examination within seven days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Intervention plus Well-Woman Exam and Peer-Delivered Intervention
Description: At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment. This group was assigned to receive a well-woman exam within seven days along with four two-hour peer-delivered educational sessions, covering health and nutrition, stress and coping, substance abuse, and HIV/AIDS.
Study: NCT01668459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel
Description: 25 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: maximum 6

Intervention type: OTHER
Group type: OTHER
Intervention: Best Supportive Care
Description: Best Supportive Care including single agent chemotherapy as determined by the patient's study physician
Study: NCT01893801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: 25 mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2 (or 50mg/m2) given intravenously (IV) on days 1 and 8 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1000mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle
Study: NCT03147846

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: delayed cord clamping
Description: delay of cord clamping for 60 seconds

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cord milking
Description: active cord milking 5 times
Study: NCT01045486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATP mixed probiotics
Description: - Patients in Group A will receive ATP mixed probiotics for 6 weeks. And after 4 weeks wash-out period, they will receive placebo for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: - Patients in Group B will receive placebo for 6 weeks. And after 4 weeks wash-out period, they will receive ATP mixed probiotics for 6 weeks
Study: NCT01909440

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Receive whole body RT

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise intervention
Description: Receive whole body RT

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutritional supplementation
Description: Given whey protein supplementation PO

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutritional supplementation
Description: Given whey protein supplementation PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03167385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: oral intake of Apatinib Mesylate 500mg once a day until progression of diesase or severe adverse effect
Study: NCT04472611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care (SOC) and Colchicine+Rosuvastatin
Description: Patients will take Rosuvastatin 40mg daily and Colchicine 0.6mg twice for 3 days and then 0.6mg daily during hospitalization
Study: NCT03908333

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: 25, 37.5, 56.25 or 75 grams/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel protein-bound
Description: 125mg/m2 over 30 minute IV infusions on days 1 and 8 repeated every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2 in 500 mL of NS over 60minute IV infusion on days 1 and 8 repeated every 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 in 500 mL over 30 minute IV infusion on days 1 and 8 repeated every 21 days
Study: NCT02455921

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neostigmine - atropine
Description: Efficacy, safety and effect on cognitive and behavioural function

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: Efficacy, safety and effect on cognitive and behavioural function
Study: NCT00454714

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: single dose Sildenafil
Description: Application of a single dose Sildenafil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single dose placebo
Description: Application of a single dose placebo
Study: NCT02458716

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Assisted Radical Prostatectomy
Description: Undergo RARP

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional open retropubic radical prostectomy
Description: Undergo conventional open RRP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)
Description: LHRH agonist or antagonist (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)
Study: NCT01778790

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Brain Stimulation with Activa PC Multi-program Neurostimulator
Description: Device: DBS 130 Hertz (Hz) frequency, 90us pulsewidth, 4 Volt (V) currency Amplitude~Device: DBS - No Stimulation (Sham) 130 Hertz (Hz)frequency, 90us pulsewidth, 0 Volt (V) currency Amplitude

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Brain Stimulation with Activa PC Multi-program Neurostimulator
Description: Device: DBS 130 Hertz (Hz) frequency, 90us pulsewidth, 4 Volt (V) currency Amplitude~Device: DBS - No Stimulation (Sham) 130 Hertz (Hz)frequency, 90us pulsewidth, 0 Volt (V) currency Amplitude
Study: NCT02837900

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPX-100 200 mg 4 times weekly for 4 weeks
Description: Ea. subject will received active TPX-100 200mg in the Left knee

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPX-100 200 mg 4 times weekly for 4 weeks
Description: Ea. subject will received active TPX-100 200mg in the Left knee

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPX-100 200 mg 4 times weekly for 4 weeks
Description: Ea. subject will received active TPX-100 200mg in the Left knee

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TPX-100 200 mg 4 times weekly for 4 weeks
Description: TPX-100 100mg Right

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPX-100 200 mg 4 times weekly for 4 weeks
Description: TPX-100 100mg Right

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TPX-100 200 mg 4 times weekly for 4 weeks
Description: TPX-100 100mg Right
Study: NCT03930836

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hand Arm Bimanual Intensive Therapy Including Lower Extremities
Description: Intensive intervention focusing on a constant bimanual coordination with a lower extremities and trunk control stimulation during play and functional activities. 50% of therapeutic time will be performed using the new interactive interface

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand Arm Bimanual Intensive Therapy Including Lower Extremities
Description: Intensive intervention focusing on a constant bimanual coordination with a lower extremities and trunk control stimulation during play and functional activities. 50% of therapeutic time will be performed using the new interactive interface

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical and occupational therapy
Description: Conventional therapy (physical and occupational therapy) is mainly based on neurodevelopmental therapeutic principles. 50% of therapeutic time will be performed using the new interactive interface
Study: NCT04335643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEACH
Description: TEACH is a remotely delivered psychological intervention. It consists of six one-hour weekly sessions that are HIPAA compliant and conducted over video conferencing.
Study: NCT01442246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin Acetate
Description: Leuprorelin Acetate 45 mg, one injection every 6 months for 24 months
Study: NCT04685798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diffusion-weighted imaging magnetic resonance imaging
Description: The research MRI study of the head and neck will be performed on a Siemens 3T MRI Scanner system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDG PET/CT
Description: Standard of care
Study: NCT00777712

Intervention type: OTHER
Intervention: Blood draw
Description: Blood will be drawn from subjects once and VAC sponge will be collected (which is normally discarded material per standard of care).
Study: NCT05072418

Intervention type: BEHAVIORAL
Intervention: Eye-opened and Eye-closed
Description: The participants were instructed to perform six 60-second trials (2 conditions × 3 trials) of maintaining an upright stance on a force plate (Kistler Type 9260A, Switzerland) under the eyes open (EO) and eyes closed (EC) conditions. The order of EO and EC was alternated for each participant, and half of the subjects began with the EO (or EC) condition. For both conditions, the participants stood with their feet 1 cm apart on a force plate and their arms relaxed comfortably at their sides.

Intervention type: BEHAVIORAL
Intervention: Eye-opened and Eye-closed
Description: The participants were instructed to perform six 60-second trials (2 conditions × 3 trials) of maintaining an upright stance on a force plate (Kistler Type 9260A, Switzerland) under the eyes open (EO) and eyes closed (EC) conditions. The order of EO and EC was alternated for each participant, and half of the subjects began with the EO (or EC) condition. For both conditions, the participants stood with their feet 1 cm apart on a force plate and their arms relaxed comfortably at their sides.
Study: NCT02520817

Intervention type: DIETARY_SUPPLEMENT
Intervention: 175 mg zinc gluconate, 50000 IU vitamin A, 500 mg vitamin C and 100 mg vitamin E once daily plus lactulose; dose 30-60 ml/day for 3 months

Intervention type: DIETARY_SUPPLEMENT
Intervention: Lactulose
Study: NCT03662958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutrate
Description: a novel leuprolide acetate 3.75mg depot

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enantone
Description: market reference leuprolide acetate 3.75 mg depot
Study: NCT02349633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06747775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06747775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06747775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06747775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Study: NCT00303823

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: defined green tea catechin extract
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04349891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electroacupuncture
Description: Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electroacupuncture
Description: Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham TEA
Description: Sham will be delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham TEA
Description: Sham will be delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions.
Study: NCT00637078

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment algorithm:caduet, Amlodipine, ACEI-ARB combo dose, a-blocker, b-blocker or spironolactone, dyslipidemic therapy with ezetamide
Description: initial treatment with a low dose diuretic/ACE-inhibitor or ARB combination followed by a low dose DHP-CCB/statin combination
Study: NCT03422835

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: R-TME
Description: Conventional Robotic Total Mesentery Excision

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: R-TaTME
Description: Robotic Transanal Total Mesentery Excision
Study: NCT02284204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam, Ketamine and Sevoflurane
Description: The combination of these three drugs were administered for the children of the intervention group in a attempt to improve the behavioral control. Midazolam and ketamine orally, sevoflurane inhaled.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam and Ketamine
Description: The combination of these two drugs were administered orally for the children of the control group.
Study: NCT03122041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Study: NCT02162550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bydureon
Description: once weekly injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once weekly injection
Study: NCT01003158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8931
Description: Tablet Oral bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8931
Description: Tablet Oral bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV once weekly for 3 weeks followed by a week off
Study: NCT02259673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fun exercise
Description: Intervention group 3 times a week for 20 minutes during 2 months, fun physical exercises (including activities carried out with the use of sports equipment such as beach ball, stretch, bird toys, etc)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fun exercise
Description: Intervention group 3 times a week for 20 minutes during 2 months, fun physical exercises (including activities carried out with the use of sports equipment such as beach ball, stretch, bird toys, etc)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fun exercise
Description: Intervention group 3 times a week for 20 minutes during 2 months, fun physical exercises~(including activities carried out with the use of sports equipment such as beach ball, stretch, bird toys, etc)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fun exercise
Description: Intervention group 3 times a week for 20 minutes during 2 months, fun physical exercises~(including activities carried out with the use of sports equipment such as beach ball, stretch, bird toys, etc)
Study: NCT01488045

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl will be administered IV according to standard procedure for colonoscopy. Initial dose will consist of no more than 50µg of Fentanyl. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more Fentanyl in no more than 50µg increments. increments.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol will be administered IV according to standard procedure for colonoscopy. The initial bolus of propofol will be up to 60 mg IV. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more sedation in 10-20 mg boluses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam will be administered IV according to standard procedure for colonoscopy. Initial dose will consist of no more than 2 mg of Midazolam. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more Midazolam in no more than 2 mg increments.
Study: NCT02541812

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: A non-invasive method for brain stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: A non-invasive method for brain stimulation